Social significance of rheumatic diseases, negative consequences for the health care system and ways of prevention
A. M. Lila,
M. A. Korolev,
I. N. Shchendrigin,
K. V. Sapozhnikov,
A. A. Lazarev,
N. A. Sableva,
D. G. Tolkacheva https://doi.org/10.37489/2782-3784-myrwd-070
EDN: HWOQXK
Abstract
Background. Immunoinflammatory rheumatic diseases (IIRDs) are a significant medical and social problem leading to high mortality, disability and economic burden for society. These diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondylitis (axSpA), significantly reduce the quality of life of patients and increase the financial burden on healthcare systems.
Objective. The aim of this systematic review is to assess current data on the risk of death in patients with IIRDs and identify factors associated with increased mortality, as well as analyze the effectiveness of biological drugs in reducing this risk.
Materials and methods. The review includes data from multiple clinical trials and meta-analyses covering the period from 2000 to 2021. The analysis was based on data collected from various sources, including national registries, clinical trials and meta-analyses.
Results. The main results show that IIRDs such as RA, PsA and axSpA significantly increase the risk of death compared to the general population (SMR 2.02 1.79; 2.29). Disease activity, smoking and comorbid conditions are key factors increasing the risk of mortality. The use of biological agents in therapy reduces the risk of death compared to no biological therapy
(HR 0.52 0.32; 0.86) and compared to methotrexate (HR 0.77 0.60; 0.97). The use of biological agents also reduces the risk of cardiovascular events and the development of dementia.
Conclusions. Early and active use of biological agents can be a significant factor in reducing the negative consequences of IRDs, including mortality and the progression of cardiovascular diseases.
Conclusion. The results of the systematic review may be useful for developing strategies for managing IIRDs and optimizing medical care for patients. The introduction of GIBPs into the treatment of IIRDs can significantly improve the prognosis and quality of life of patients, reducing the risk of mortality and other adverse outcomes.
Keywords
immune-mediated inflammatory rheumatic diseases,
rheumatoid arthritis,
psoriatic arthritis,
axial spondyloarthritis,
mortality,
genetically engineered biological drugs,
disability,
dementia
Supporting agencies: The work was carried out without sponsorship
About the Authors
A. M. Lila
Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education
Russian Federation
Competing Interests:
Russian Federation
Alexander M. Lila, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Director of the Institute, Head of the Department
Rheumatology Department
Moscow
Competing Interests:
The authors declare no conflict of interest
M. A. Korolev
Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
Maxim A. Korolev, Dr. Sci. (Med.), Professor, Head of the Institute
Research Institute of Clinical and Experimental Lymphology
Novosibirsk
Competing Interests:
The authors declare no conflict of interest
I. N. Shchendrigin
Induction Center for Responsible Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Ivan N. Shchendrigin, Cand. Sci. (Med.), Chief Physician
Stavropol
Competing Interests:
The authors declare no conflict of interest
K. V. Sapozhnikov
Kirov Military Medical Academy
Russian Federation
Competing Interests:
Russian Federation
Kirill V. Sapozhnikov, Cand. Sci. (Med.), Lecturer
Department of Automation of Management of Medical Service with Military Medical Statistics
Saint Petersburg
Competing Interests:
The authors declare no conflict of interest
A. A. Lazarev
Saint Petersburg State University of Telecommunications named after prof. M. A. Bonch-Bruevich,
Russian Federation
Competing Interests:
Russian Federation
Andrey A. Lazarev, 2nd year postgraduate student
St. Petersburg
Competing Interests:
The authors declare no conflict of interest
N. A. Sableva
Russian Presidential Academy of National Economy and Public Administration
Russian Federation
Competing Interests:
Russian Federation
Natalia A. Sableva, independent expert of research projects
North-West Institute of Management; Project Office
Moscow
Competing Interests:
The authors declare no conflict of interest
D. G. Tolkacheva
Russian Presidential Academy of National Economy and Public Administration
Russian Federation
Competing Interests:
Russian Federation
Daria G. Tolkacheva, independent expert of research projects
North-West Institute of Management; Project Office
Moscow
Competing Interests:
The authors declare no conflict of interest
References
1. Muravyov Yu.V. Extra-articular manifestations of rheumatoid arthritis. Scientific and practical rheumatology. 2018;56(3):356–362. (In Russ.) doi: 10.14412/1995-4484-2018-356-362.
2. Nasonov EL. Achievements of rheumatology in the 21<sup>st</sup> century. Scientific and practical rheumatology. 2014;52(2):133–140. (In Russ.) doi: 10.14412/1995-4484-2014-133-140.
3. Nasonov EL. Progress of rheumatology at the beginning of the 21<sup>st</sup> century. Modern rheumatology. 2014; (3):4–8. (In Russ.) doi: 10.14412/1996-7012-2014-3-4-8.
4. Hsieh PH, Wu O, Geue C, McIntosh E, McInnes IB, Siebert S. Economic burden of rheumatoid arthritis : a systematic review of literature in biologic era. Ann Rheum Dis. 2020 Jun;79(6):771-777. doi: 10.1136/annrheumdis-2019-216243.
5. Sokka T, Kautiainen H, Möttönen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol. 1999 Aug;26(8):1681-5.
6. Kłak A, Raciborski F, Samel-Kowalik P. Social implications of rheumatic diseases. Reumatologia. 2016;54(2):73-8. doi: 10.5114/reum.2016.60216.
7. Tomek D et al. Understanding Patients’ Socio-Economic Burden in Rheumatic Diseases. Value in Health, Volume 18, Issue 7, A651 - A652.
8. Fyrand L, Moum T, Finset A, Glennås A. The impact of disability and disease duration on social support of women with rheumatoid arthritis. J Behav Med. 2002 Jun;25(3):251-68. doi: 10.1023/a:1015380711375.
9. Galushko EA, Nasonov EL. Prevalence of rheumatic diseases in Russia. Almanac of Clinical Medicine. 2018;46(1):32-39. (In Russ.) doi: 10.18786/2072-0505-2018-46-1-32-39.
10. Rodriguez-Rodriguez L, Leon L, Ivorra-Cortes J, Gómez A, Lamas JR, Pato E, Jover JÁ, Abásolo L. Treatment in rheumatoid arthritis and mortality risk in clinical practice: the role of biologic agents. Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1026-1032.
11. Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, Geborek P. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2007 May;66(5):670-5. doi: 10.1136/ard.2006.062497.
12. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008 Dec 15;59(12):1690-7. doi: 10.1002/art.24092.
13. Ward MM. Interpreting studies of cardiovascular mortality in rheumatoid arthritis: the importance of timing. Arthritis Rheum. 2008 Dec 15;59(12):1687-9. doi: 10.1002/art.24170.
14. Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, Visser M, Stehouwer CD, Dekker JM, Nijpels G, Heine R, Dijkmans BA, Nurmohamed MT. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum. 2009 Nov 15;61(11):1571-9. doi: 10.1002/art.24836.
15. Hippisley-Cox J, Coupland CAC, Bafadhel M, Russell REK, Sheikh A, Brindle P, Channon KM. Development and validation of a new algorithm for improved cardiovascular risk prediction. Nat Med. 2024 May;30(5):1440-1447. doi: 10.1038/s41591-024-02905-y.
16. Zegkos T, Kitas G, Dimitroulas T. Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Ther Adv Musculoskelet Dis. 2016 Jun;8(3):86-101. doi: 10.1177/1759720X16643340.
17. van Nies JA, de Jong Z, van der Helm-van Mil AH, Knevel R, Le Cessie S, Huizinga TW. Improved treatment strategies reduce the increased mortality risk in early RA patients. Rheumatology (Oxford). 2010 Nov;49(11):2210-6. doi: 10.1093/rheumatology/keq250.
18. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011 Apr;63(4):522-9. doi: 10.1002/acr.20371.
19. Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, Strangfeld A. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015 Feb;74(2): 415-21. doi: 10.1136/annrheumdis-2013-204021.
20. Xie W, Hou Y, Xiao S, Zhang X, Zhang Z. Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia : a systematic review with meta-analysis. RMD Open. 2024 Feb 27;10(1):e004016. doi: 10.1136/rmdopen-2023-004016.
21. England BR, Sayles H, Michaud K, Caplan L, Davis LA, Cannon GW, Sauer BC, Solow EB, Reimold AM, Kerr GS, Schwab P, Baker JF, Mikuls TR. Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Jan;68(1):36-45. doi: 10.1002/acr.22642.
22. Nomeir AM, Turner R, Watts E, Smith D, West G, Edmonds J. Cardiac involvement in rheumatoid arthritis. Ann Intern Med. 1973 Dec;79(6):800-6. doi: 10.7326/0003-4819-79-6-800.
23. van den Hoek J, Boshuizen HC, Roorda LD, Tijhuis GJ, Nurmohamed MT, van den Bos GA, Dekker J. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int. 2017 Apr;37(4):487-493. doi: 10.1007/s00296-016-3638-5.
24. Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990<sup>s</sup> . Ann Rheum Dis. 2005 Nov;64(11):1595-601. doi: 10.1136/ard.2004.034777.
25. Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation. 2004 Sep 28;110(13):1774-9. doi: 10.1161/01.CIR.0000142864.83780.81.
26. Mattey DL, Glossop JR, Nixon NB, Dawes PT. Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2007 Dec;56(12):3940-8. doi: 10.1002/art.23075.
27. Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol. 2004;33(4):221-7. doi: 10.1080/03009740410005845. Erratum in: Scand J Rheumatol. 2006 Jul-Aug;35(4):332.
28. Humphreys JH, Warner A, Chipping J, Marshall T, Lunt M, Symmons DP, Verstappen SM. Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken). 2014 Sep;66(9):1296-301. doi: 10.1002/acr.22296. Erratum in: Arthritis Care Res (Hoboken). 2015 Jan;67(1):135.
29. Toledano E, Candelas G, Rosales Z, Martínez Prada C, León L, Abásolo L, Loza E, Carmona L, Tobías A, Jover JÁ. A meta-analysis of mortality in rheumatic diseases. Reumatol Clin. 2012 Nov-Dec;8(6):334-41. doi: 10.1016/j.reuma.2012.05.006.
30. Bournia VK, Fragoulis GE, Mitrou P, Mathioudakis K, Tsolakidis A, Konstantonis G, Vourli G, Paraskevis D, Tektonidou MG, Sfikakis PP. All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019. RMD Open. 2021 Nov;7(3):e001694. doi: 10.1136/rmdopen-2021-001694.
31. Dadonienė J, Charukevič G, Jasionytė G, Staškuvienė K, Miltinienė D. Mortality in Inflammatory Rheumatic Diseases: Lithuanian National Registry Data and Systematic Review. Int J Environ Res Public Health. 2021 Nov 24;18(23):12338. doi: 10.3390/ijerph182312338.
32. Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 2014 Oct;44(2):208-19. doi: 10.1016/j.semarthrit.2014.05.010.
33. Meissner Y, Schäfer M, Albrecht K, Kekow J, Zinke S, Tony HP, Strangfeld A. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register. RMD Open. 2023 Oct;9(4):e003489. doi: 10.1136/rmdopen-2023-003489.
34. Sánchez-Piedra C, Sueiro-Delgado D, García-González J, Ros-Vilamajo I, Prior-Español A, Moreno-Ramos MJ, Garcia-Magallon B, Calvo-Gutiérrez J, Perez-Vera Y, Martín-Domenech R, Ruiz-Montesino D, Vela-Casasempere P, Expósito L, Sánchez-Alonso F, González-Davila E, Díaz-González F. Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years. Sci Rep. 2021 Jul 23;11(1): 15051. doi: 10.1038/s41598-021-94504-x.
Review
For citations:
Lila A.M., Korolev M.A., Shchendrigin I.N., Sapozhnikov K.V., Lazarev A.A., Sableva N.A., Tolkacheva D.G. Social significance of rheumatic diseases, negative consequences for the health care system and ways of prevention. Real-World Data & Evidence. 2025;5(2):5-15. (In Russ.) https://doi.org/10.37489/2782-3784-myrwd-070. EDN: HWOQXK
Views:
57
Email this article 
Post a Comment 